To investigate the role of uridine in osteoclast differentiation and its potential as a therapeutic agent for osteoporosis, emphasizing its implications for treatment strategies.
Key Findings:
Uridine levels significantly decline upon RANKL stimulation during osteoclast differentiation, indicating its role in metabolic remodeling.
Exogenous uridine supplementation suppresses osteoclast development and resorptive function.
Uridine administration improves trabecular microarchitecture and reduces osteoclast burden in OVX mice.
Uridine plays a critical and novel role in modulating osteoclast differentiation through its effects on ROS and the PI3K/Akt–FoxO signaling pathway, suggesting its potential as a therapeutic agent for osteoporosis.
Limitations:
The study primarily focuses on in vitro and animal models, which may not fully replicate human conditions.
Further clinical studies are needed to validate the efficacy and safety of uridine supplementation in diverse human populations.
Conclusion:
Uridine emerges as a promising metabolic regulator for osteoporosis treatment, linking pyrimidine metabolism with osteoclast differentiation.
